Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1226 for Post-COVID-19 Respiratory Symptoms
NCT04949386Phase 2Unknown
- Sponsor
- SolAeroMed
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Device-based Delivery
01
Overview
A Phase 2 trial of S-1226 in post acute COVID-19 syndrome, sponsored by SolAeroMed. Status: unknown.
02
Drugs
S-1226
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04949386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949386.